Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
34.95 USD +2.64% Intraday chart for Spyre Therapeutics, Inc. +5.97% +62.41%
May. 15 Spyre Therapeutics, Inc. Announces Board Changes CI
May. 13 Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
AQ
Spyre Therapeutics, Inc. Announces Board Changes
CI
Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating
MT
Spyre Therapeutics: Q1 Earnings Snapshot
AQ
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Spyre Therapeutics Announces Grants of Inducement Awards
AQ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target
MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares
MT
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating
MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding
CI
North American Morning Briefing : Powell Still in -2-
DJ
Spyre Therapeutics Announces Grants of Inducement Awards
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.